

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

Highlights of revised protocols and PPPOs –
Gastrointestinal protocol optimization

Cancer Drug Manual[®]

New: Irinotecan Liposomal **Revised:** Etoposide,
Irinotecan Liposomal **Editorial Board:** New nursing
member

REVISED Protocols, PPPOs and Patient Handouts

CN CNAJ12TZRT | **GI** GICAPRI, GIAAVCT, GIAJCAP,
GIAJCAPOX, GIAJFFOX, GIAJFL, GIAJRALOX, GIAVCRT,
GIAVFL, GIAVRALIR, GIAVRALOX, GIAVTZCAP, GICART,
GICPART, GIENDO2, GIFOLFOX, GIFUART, GIFUPART,
GIGAVCC, GIIR, GIIRINALT, UGINETEV, GIOCTLAR, GIPE,
GIPNEVER, GIPNSUNI, GIRAJCOX, GIRAJFFOX, GIRALT,
GIRCAP, GIRCRT, GIRINFRT | **GO** UGOCXCATBP | **GU**
GUEDPM, GUFUPRT, GUSCPERT | **SA** SAVAC | **SC**
SCHBV, SCICANS

Correction

July Issue: Typo of Protocol Code – GIVACAP should
read "GIAVCAP"

Resources and Contact Information

Editor's Choice

Highlights of Revised Protocols and PPPOs

The Gastrointestinal Tumour Group is continuing its protocol optimization in August, with testing simplification and alignment of the adjuvant and advanced colorectal, carcinoid and neuroendocrine tumor protocols. Notable changes include removal of mandatory electrolyte monitoring in numerous protocols and clarification of emetogenic risk categories. The GIOCTLAR protocol and PPPOs were also updated to clarify the availability of a 3-weekly dosing option in the event of breakthrough symptoms.

All documents are available in the [Cancer Drug Manual[©]](#) on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Monograph, Patient Handout, and entry for the Chemotherapy Preparation and Stability Chart are made available for your reference only.

The **Irinotecan Liposomal Monograph** and **Patient Handout** have been developed. Expert review was provided by Dr. Sharlene Gill (medical oncologist, BC Cancer GI Group) and Megan Darbyshire (Tumour Group Pharmacist, BC Cancer Provincial Pharmacy). In this formulation, irinotecan is encapsulated in a lipid bilayer vesicle called a liposome. Irinotecan liposome is used in the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin. The usual dosing is 70 mg/m² IV given on day 1 of a 14-day cycle.

Highlights from these documents include:

- irinotecan liposomal is **NOT interchangeable** with conventional irinotecan. Do NOT substitute for or with any other irinotecan formulations
- **late onset diarrhea** can be life threatening and requires prompt initiation of loperamide
- starting dose reduction should be considered in patients known to be **homozygous for UGT1A1*28 allele**
- nomenclature has been changed from “liposome” to “liposomal” to align with Cerner build

Irinotecan liposomal has been added to the **Chemotherapy Preparation and Stability Chart**, and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Etoposide Monograph

Pharmacokinetics: deleted information regarding drug administration as not related to pharmacokinetics

Uses: updated indications per current reference sources

Special Precautions (Contraindications): removed history of prior hypersensitivity as not considered a contraindication

Cautions: removed non-interchangeability bullet as etoposide phosphate has been added as an alternative to all BC Cancer etoposide protocols in cases of hypersensitivity to etoposide; updated carcinogenicity, pregnancy, fertility, breastfeeding and deleted FDA Pregnancy Category as no longer used by FDA

Side Effects: updated references for extravasation hazard and emetogenic potential in table; updated allergic reactions paragraph to include statement about substituting etoposide phosphate; updated formatting of excipient-related side effects paragraph; and added new paragraph about extravasation.

Parenteral Administration: deleted information pertaining to final concentration (preparation instructions are found in the *Chemotherapy Preparation and Stability Chart*)

Dosage Guidelines: completely revised section (expert review of *Children's Dosing* provided by Jennifer Kendrick, Clinical Pharmacy Specialist, BC Children's Hospital)

Cancer Drug Manual[®]

Chemotherapy Preparation and Stability Chart

Irinotecan liposomal: updated manufacturer and preparation instructions per current product information

CDM Editorial Board Changes

The Cancer Drug Manual[®] Editorial Review Board would like to welcome **Brittany Freeman** (Provincial Nurse Educator) as our newest Editorial Board member. Brittany joins us from the BC Cancer Prince George regional centre. Welcome Brittany!

List of Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
CN Neuro-Oncology				
CNAJ12TZRT	Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	--
GI Gastrointestinal				
GICAPRI	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan and Capecitabine in Patients Unsuited for GIFOLFIRI	<i>Tests updated, antiemetic risk category and treatment clarified, dose modifications updated</i>	<i>Tests updated</i>	--
GIAAVCT	First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma Using CARBOplatin and Weekly PACLitaxel	<i>Eligibility clarified, tests and dose modifications updated</i>	<i>Tests updated</i>	--
GIAJCAP	Adjuvant Therapy of Colon Cancer using Capecitabine	<i>Eligibility clarified, tests updated, antiemetic risk category clarified</i>	<i>Tests updated</i>	--
GIAJCAPOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin and Capecitabine	<i>Eligibility clarified, tests updated, antiemetic risk category and treatment clarified</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
GIAJFOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Eligibility clarified, tests updated, antiemetic risk category updated</i>	<i>Tests updated</i>	--
GIAJFL	Adjuvant Therapy of Colon Cancer using Fluorouracil Injection and Infusion and Leucovorin Infusion	<i>Eligibility clarified, tests, physician contact, and link in footer updated</i>	<i>Tests updated</i>	--
GIAJRALOX	Adjuvant Combination Chemotherapy for Node Positive Colon Cancer Using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	<i>Eligibility clarified, tests updated, antiemetic risk category clarified, physician contact updated</i>	<i>Tests updated</i>	--
GIAVCRT	Combined Modality Therapy for Metastatic Rectal Carcinoma using Capecitabine and Radiation Therapy	<i>Eligibility clarified, tests updated</i>	<i>Tests updated</i>	--
GIAVFL	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Fluorouracil Injection and Infusion and Leucovorin Infusion	<i>Eligibility clarified, tests, treatment, dose modifications updated</i>	<i>Tests updated</i>	--
GIAVRALIR	Palliative Therapy of Metastatic Colorectal Cancer using Irinotecan and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	<i>Eligibility clarified, tests updated, antiemetic risk category clarified</i>	<i>Tests updated</i>	--
GIAVRALOX	Palliative Therapy of Metastatic Colorectal Cancer using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	<i>Eligibility clarified, tests updated, antiemetic risk category clarified</i>	<i>Tests updated</i>	--
GIAVTZCAP	Palliative Therapy of Metastatic Neuroendocrine Cancer using Temozolomide and Capecitabine	<i>Eligibility clarified, tests and premedications updated</i>	<i>Tests updated</i>	--
GICART	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy	<i>Eligibility clarified, tests, premedications, and link in footer updated</i>	<i>Tests updated</i>	--
GICPART	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using CISplatin, Capecitabine and Radiation Therapy	<i>Eligibility clarified, tests and premedications updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
GIENDO2	Palliative Therapy for Pancreatic Endocrine Tumours using Streptozocin and DOXOrubicin	<i>Eligibility clarified, tests, physician contact and link in footer updated</i>	<i>Tests updated</i>	--
GIFOLFOX	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Tests updated, antiemetic risk category clarified</i>	<i>Tests updated</i>	--
GIFUART	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Infusional Fluorouracil and Radiation Therapy	<i>Eligibility clarified, tests, premedications, and link in footer updated</i>	<i>Tests updated</i>	--
GIFUPART	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using CISplatin, Infusional Fluorouracil and Radiation Therapy	<i>Eligibility clarified, tests and link in footer updated</i>	<i>Tests updated</i>	--
GIGAVCC	Palliative Therapy of Metastatic or Locally Advanced Anal Squamous Cell Carcinoma using CISplatin and Capecitabine	<i>Eligibility clarified, tests updated</i>	<i>Tests updated</i>	--
GIIR	Palliative Chemotherapy of Metastatic Colorectal Cancer using Irinotecan	<i>Eligibility clarified, tests updated</i>	<i>Tests updated</i>	--
GIIRINALT	Palliative Chemotherapy of Metastatic Colorectal Cancer using Weekly Irinotecan	<i>Eligibility clarified, tests updated, antiemetic risk category clarified, physician contact updated</i>	<i>Tests updated</i>	--
UGINETEV	Treatment of Advanced Neuroendocrine Tumours of Gastrointestinal Origin (Non-Functional) Using Everolimus	<i>Eligibility and treatment duration clarified, tests, dose modifications, precautions, and physician contact updated</i>	<i>Dispense quantity, return appointment, and tests updated</i>	--
GIOCTLAR	Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumors of the GI Tract using Octreotide Long Acting	<i>Eligibility note added, treatment and dose modifications updated)</i>	<i>Added dosing interval options</i>	--
GIPE	Palliative Therapy of Neuroendocrine Tumours using CISplatin and Etoposide	<i>Eligibility clarified, tests and premedications updated</i>	<i>Premedications and tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
GIPNEVER	Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using Everolimus	<i>Eligibility and treatment duration clarified, tests, dose modifications, precautions, and physician contact updated</i>	<i>Dispense quantity, return appointment, and tests updated</i>	--
GIPNSUNI	Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib	<i>Eligibility clarified, tests updated, antiemetic risk category clarified, physician contact updated</i>	<i>Dispense quantity, return appointment, and tests updated</i>	--
GIRAJCOX	Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin and Capecitabine	<i>Eligibility clarified, tests updated, antiemetic risk category and treatment clarified</i>	<i>Tests updated</i>	--
GIRAJFOX	Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Eligibility clarified, tests updated, antiemetic risk category clarified</i>	<i>Tests updated</i>	--
GIRALT	Palliative Chemotherapy for Metastatic Colorectal Cancer using Raltitrexed in Patients with Previous Fluorouracil Toxicity	<i>Eligibility clarified, tests updated, antiemetic risk category clarified</i>	<i>Tests updated</i>	--
GIRCAP	Adjuvant Therapy for Stage II and III Rectal Cancer using Capecitabine in Patients Previously Treated with Preoperative Radiation Therapy Alone	<i>Eligibility clarified, tests and dose modifications updated</i>	<i>Tests updated</i>	--
GIRCRT	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy	<i>Eligibility clarified, tests and link in footer updated</i>	<i>Tests updated</i>	--
GIRINFRT	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine, Infusional Fluorouracil and Radiation Therapy	<i>Eligibility clarified, tests updated, link in footer updated</i>	<i>Tests updated</i>	--
GO Gynecologic				
UGOCXCATBP	Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab	--	<i>Bevacizumab infusion time clarified</i>	--

GU | Genitourinary

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GUEDPM	Treatment of Metastatic Adrenocortical Cancer with Etoposide, DOXOrubicin, CISplatin and Mitotane	<i>Tests updated, pre and post hydration added</i>	<i>Tests updated</i>	--
GUFUPRT	Combined Modality Therapy for Squamous Cell Cancer of the Genitourinary System using Fluorouracil and CISplatin with Radiation	<i>Tests, premedications, dose modifications updated</i>	<i>Premedications updated</i>	<i>Antiemetic instructions updated</i>
GUSCPERT	Therapy of Genitourinary Small Cell Tumors with a Platinum and Etoposide with Radiation	<i>Title, premedications, tests, treatment, dose modifications updated</i>	<i>Premedications updated</i>	<i>Antiemetic instructions updated</i>
SA Sarcoma				
SAVAC	Treatment of Sarcomas with vinCRISline, DOXOrubicin and Cyclophosphamide (SAVAC)	<i>Cyclophosphamide diluent updated, minor formatting</i>	<i>Cyclophosphamide diluent updated, minor formatting</i>	--
SC Supportive Care				
SCHBV	Hepatitis B Virus Reactivation Prophylaxis	<i>Tests and appendix updated</i>	--	--
SCICANS	Immune Effector Cell-Associated Neurotoxicity Syndrome Management	<i>ICANS assessment section removed, tests, treatment and appendix updated</i>	<i>Monitoring and management updated</i>	--

Correction

July Issue

Typos in Protocol Codes under “Inside This Issue” and “Editor’s Choice” Sections: “GIVACAP” should read “GIAVCAP”.

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638	nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@ehcnet.phsa.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247	mclin@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)
 Jelena Mucovic, BScPharm (Assistant Editor)
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC
 Alison Pow, BScPharm
 Yuna Jang, RN